Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Sunil R. Hingorani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3869-8729; OpenAlex author ID A5013925502, A5157667232, A5160298607; NIH RePORTER profile ID 1926329. Sources: funder_awards.

Their work

Papers
32 (first author 4, last author 9)
Trials
0
Grants
9
Labs led
3
Collaborators
122
Papers, trials and grants by year

2005: 1 grant · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 grant · 2012: 2 papers · 2013: 2 papers, 2 grants · 2014: 1 paper · 2015: 4 papers · 2016: 4 papers · 2017: 2 papers, 1 grant · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper, 2 grants · 2022: 2 papers, 1 grant · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 4 papers, 1 grant

Papers 32

  1. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2-deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2026-015489↗
  2. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Last author DOI 10.3390/cancers18030507↗
  3. Combination Immunotherapy Enhances Serial Radiofrequency Ablation Induced Systemic Antitumor Immunity in Pancreatic Cancer Co-author DOI 10.64898/2026.04.05.713683↗
  4. HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α Co-author DOI 10.64898/2026.10.02.754697↗
  5. Improving outcomes of patients with pancreatic cancer. Co-author DOI 10.1038/s41571-025-01019-9↗
  6. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  7. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Co-author DOI 10.1038/s41568-022-00530-w↗
  8. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003525↗
  9. Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-21-0601↗
  10. Cx43 phosphorylation sites regulate pancreatic cancer metastasis. First author DOI 10.1038/s41388-021-01668-x↗
  11. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  12. Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets. First author DOI 10.1053/j.gastro.2018.12.044↗
  13. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2326-6066.cir-18-0448↗
  14. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Co-author DOI 10.1200/jco.18.01295↗
  15. Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11060772↗
  16. Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. Co-author DOI 10.1080/02656736.2017.1336675↗
  17. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
  18. Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1615↗
  19. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2326-6066.cir-16-0322↗
  20. Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. Last author DOI 10.1016/j.bpj.2016.03.040↗
  21. Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2016.03.040↗
  22. RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma. First author DOI 10.1080/23723556.2015.1076588↗
  23. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-2010↗
  24. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.ccell.2015.09.022↗
  25. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.cell.2015.04.048↗
  26. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-0296↗
  27. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with meta… Co-author DOI 10.1634/theoncologist.2014-0394↗
  28. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Last author DOI 10.1136/gutjnl-2013-306271↗
  29. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-11-1433↗
  30. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Co-author DOI 10.1158/1940-6207.capr-13-0157↗
  31. Changes in connexin43 expression and localization during pancreatic cancer progression. First author DOI 10.1007/s00232-012-9446-2↗
  32. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ccr.2012.01.007↗

Grants 9

  1. OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER R01CA161112↗
  2. Investigating the metastatic drive in pancreas cancer R01CA223483↗
  3. Murine Clinical Trials for the Evaluation of High Priority Therapeutic Targets for Precision Promise AWARD pancan:2021-sunil-r-hingorani-md-phd-murine-clinical-trials-for-the-evaluatio
  4. Stopping PDA progression using inhibitors of CSC dissemination and immunotherapy U01CA224193↗
  5. Combining Stromal Disruption and Relief of Immune Suppression to Treat PDA AWARD pancan:2017-sunil-hingorani-combining-stromal-disruption-and-relief-
  6. Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma R01CA129357↗
  7. Peripheral blood biopsy for molecular diagnosis of pancreatic cancer R21CA159240↗
  8. Dissecting the roles of stellate cells in pancreas cancer progression R21CA152249↗
  9. The Cell-of-Origin in Pancreatic Cancer AWARD pancan:2005-sunil-r-hingorani-md-phd-the-cell-of-origin-in-pancreatic-cancer

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martin C. Whittle · 5 shared papers, 2015–2026 · strength 0.66
  2. Ingunn M. Stromnes · 6 shared papers, 2014–2026 · strength 0.66
  3. Philip D. Greenberg · 6 shared papers, 2014–2026 · strength 0.66
  4. Sita Kugel · 3 shared papers, 2025–2026 · strength 0.64
  5. Elena Gabriela Chiorean · 4 shared papers, 2015–2026 · strength 0.54
  6. Paolo Provenzano · 4 shared papers, 1 shared grant, 2011–2026 · strength 0.53
  7. Adam L. Burrack · 3 shared papers, 2019–2026 · strength 0.47
  8. Rachael Ann Safyan · 2 shared papers, 2025–2026 · strength 0.42
  9. Nina G. Steele · 2 shared papers, 2025–2026 · strength 0.41
  10. Naomi Yamamoto · 2 shared papers, 2025–2026 · strength 0.41
  11. Stephanie Dobersch · 2 shared papers, 2025–2026 · strength 0.41
  12. Ian M. Loveless · 2 shared papers, 2025–2026 · strength 0.41
  13. Faiyaz Notta · 2 shared papers, 2025–2026 · strength 0.41
  14. Howard C. Crawford · 2 shared papers, 2025–2026 · strength 0.41
  15. Christopher C. DuFort · 4 shared papers, 2016–2022 · strength 0.38
  16. Andrew Eugene Hendifar · 3 shared papers, 2018–2026 · strength 0.37
  17. Stephan B. Dreyer · 1 shared paper, 2025 · strength 0.37
  18. Andrew Victor Biankin · 1 shared paper, 2025 · strength 0.37
  19. Howard S. Höchster · 2 shared papers, 2019–2026 · strength 0.31
  20. Joell L. Solan · 2 shared papers, 2012–2021 · strength 0.27
  21. Paul D. Lampe · 2 shared papers, 2012–2021 · strength 0.27
  22. Urvinder Kaur Sardarni · 1 shared paper, 2026 · strength 0.23
  23. Khadija Shahab Turabi · 1 shared paper, 2026 · strength 0.23
  24. Lincoln N. Strickland · 1 shared paper, 2026 · strength 0.23
  25. Jesse L. Cox · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.